1222 ET - The failure of Wainua, a heart disease drug developed by AstraZeneca and Ionis, to meet a primary endpoint in a phase 3 trial is a positive for both BridgeBio Pharma and Alnylam Pharmaceuticals, according to Jefferies analysts. For BridgeBio, the news is a potential clearing event for its Attruby drug, an oral stabilizer that addresses the same rare heart disease known as transthyretin amyloid cardiomyopathy. It's also a headwind for Alnylam, whose Amvuttra treatment will remain the only gene silencer for ATTR-CM, the analysts write, although long-term questions remain for the company's next-generation silencer. Alnylam stock is up 2.4%, erasing some gains after opening up 16%. BridgeBio shares gain 15%. (elias.schisgall@wsj.com)
(END) Dow Jones Newswires
July 09, 2026 12:21 ET (16:21 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
